Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Steroidal compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3-pyridyl)borane, which are potent inhibitors of human testicular 17 alpha-hydroxylase-C17,20-lyase. The requirement for these structural features is stringent: compounds having 2-pyridyl (9), 4-pyridyl (10), or 2-pyridylmethyl (11) substituents instead of the 3-pyridyl substituent were either poor inhibitors or noninhibitory. Reduction of the 16,17-double bond to give 17 beta-pyridyl derivatives diminished potency with 3-pyridyl substitution (3-->27; IC50 for lyase, 2.9-->23 nM) but increased it with a 4-pyridyl substituent present (10-->28; IC50 1 microM-->53 nM). In contrast, a variety of substitution patterns in rings A-C of the steroid skeleton afforded inhibitors having potencies similar to those most closely related structurally to the natural substrates pregnenolone and progesterone, respectively 17-(3-pyridyl)androsta-5,16-dien-3 beta-ol (3, Kiapp < 1 nM; IC50 for lyase, 2.9 nM) and 17-(3-pyridyl)androsta-4,16-dien-3-one (15; IC50 for lyase, 2.1 nM). Thus compounds having variously aromatic ring A (18), saturated rings A/B (21, 22), and oxygenated ring C (26) exhibited IC50 values for lyase (1.8-3.0 nM) falling within a 2-fold range. The most potent compounds are candidates for development as drugs for the treatment of hormone-dependent prostatic carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [11]
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Palladium-catalyzed cross-coupling reaction of organoboron compounds with organic triflates
Ohe, T., Miyaura, N., & Suzuki, A. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00060a041 · Cited by 321
A method for the regiospecific synthesis of enol triflates by enolate trapping
Mc Murry, J. E., & Scott, W. J. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81581-6 · Cited by 285
THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS
Goldstein, A. (1944) · Journal of General Physiology · doi:10.1085/jgp.27.6.529 · Cited by 181
KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER
Trachtenberg, J., & Pont, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92909-x · Cited by 162
Steroid Hormones: A Practical Approach
(1989) · Tumori Journal · doi:10.1177/030089168907500230 · Cited by 100
Labrie, F., Belanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6 · Cited by 94
Is there a case for P-450 inhibitors in cancer treatment?
Wauwe, J. P. V., & Janssen, P. A. J. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a001 · Cited by 88
FORTI, G., SALERNO, R., MONETI, G., ZOPPI, S., FIORELLI, G., MARINONI, T., NATALI, A., COSTANTINI, A., SERIO, M., MARTINI, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
An Efficient Synthesis of 3-Heteroarylpyridines via Diethyl-(3-pyridyl)-borane
Ishikura, M., Kamada, M., & Terashima, M. (1984) · Synthesis · doi:10.1055/s-1984-31026 · Cited by 75
Fan, D.-F., Oshima, H., Troen, B. R., & Troen, P. (1974) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(74)90182-9 · Cited by 73
Mechanism of Inhibition of Human Testicular Steroidogenesis by Oral Ketoconazole∗
RAJFER, J., SIKKA, S. C., RIVERA, F., & HANDELSMAN, J. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-5-1193 · Cited by 69
Analogs of aminoglutethimide: selective inhibition of cholesterol side-chain cleavage
Foster, A. B., Jarman, M., Leung, C. S., Rowlands, M., & Taylor, G. N. (1983) · Journal of Medicinal Chemistry · doi:10.1021/jm00355a011 · Cited by 68
Self-citationNew Methods of Endocrine Management of Prostatic Cancer
Smith, J. A. J. (1987) · The Journal of Urology · doi:10.1016/s0022-5347(17)43855-9 · Cited by 67
Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid
McCague, R., Rowlands, M. G., Barrie, S. E., & Houghton, J. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a022 · Cited by 60
Self-citationA novel synthesis of 4-aryl- and 4-heteroarylpyridines via diethyl(4-pyridyl)borane.
Ishikura, M., OHTA, T., & Terashima, M. (1985) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.33.4755 · Cited by 51
Fitton, P., McKeon, J. E., & Ream, B. C. (1969) · Journal of the Chemical Society D Chemical Communications · doi:10.1039/c29690000370 · Cited by 48
Rationally Designed Analogs of Tamoxifen with Improved Calmodulin Antagonism
Hardcastle, I. R., Rowlands, M., Houghton, J., Parr, I. B., Potter, G. A., Jarman, M., Edwards, K. J., Laughton, C. A., Trent, J. O., & Neidle, S. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00002a005 · Cited by 40
Self-citationPreparation of 2- and 4-Picolyllithium
Beumel, O. F., Smith, W. N., & RYBALKA, B. (1974) · Synthesis · doi:10.1055/s-1974-23236 · Cited by 33
Steroidal androgen biosynthesis inhibitors
Arth, G. E., PATCHETT, A. A., Jefopoulus, T., Bugianesi, R. L., Peterson, L. H., Ham, E. A., Kuehl, F. A., & Brink, N. G. (1971) · Journal of Medicinal Chemistry · doi:10.1021/jm00290a003 · Cited by 33
Mechanism and control of rat testicular steroid synthesis.
Chasalow, F. I. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30174-6 · Cited by 32
Jubelirer, S. J., & Hogan, T. F. (1989) · The Journal of Urology · doi:10.1016/s0022-5347(17)38669-x · Cited by 31
BOSSCHE, H. V., Willemsens, G., Bellens, D., Roels, I., & Janssen, P. A. J. (1990) · Biochemical Society Transactions · doi:10.1042/bst0180010 · Cited by 29
Laughton, C. A., & Neidle, S. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a023 · Cited by 28
Li, J., Li, Y., Son, C., Banks, P. K., & Brodie, A. M. H. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90134-5 · Cited by 27
A new assay and solubilization procedure for steroid 17,20-lyase from rat testes
Chasalow, F. I., Marr, H. B., & Taylor, G. F. (1982) · Steroids · doi:10.1016/0039-128x(82)90133-7 · Cited by 24
Studies of the human testis. XIV. Properties of C17-C20 lyase
Hosaka, M., Oshima, H., & Troen, P. (1980) · European Journal of Endocrinology · doi:10.1530/acta.0.0940389 · Cited by 19
GOLDMAN, A. S., Eavey, R. D., & Baker, M. K. (1976) · Journal of Endocrinology · doi:10.1677/joe.0.0710289 · Cited by 19
Synthesis of 17b-Pyridyl- and 17b-Pyridonyl-androstane Derivatives
Wicha, J., & Masnyk, M. (1981) · Heterocycles · doi:10.3987/r-1981-04-0521 · Cited by 9
The selective protection of the 3-ketone functions of steroids as heptafluoro-p-tolyl enol ethers
Jarman, M., & McCague, R. (1987) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19870001129 · Cited by 6
Self-citationKetoconazole High Dose in the Hormonal Treatment of Advanced Carcinoma of the Prostate
Hassellund, S., Norman, N., & Sander, S. (1987) · Scandinavian Journal of Urology and Nephrology · doi:10.3109/00365598709180781 · Cited by 2
Potter, G. A., & McCague, R. (1991) · ChemInform · doi:10.1002/chin.199119140 · Cited by 1
Self-citation
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
“Cardiac disorder* 106 (13) 26 (3) 7 (1) 42 (11) 7 (2) 2 (<1)”
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Metadata
- Authors
- Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-06
- Volume
- 38
- Issue
- 13
- Pages
- 2463-2471
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2027081726
- Cited by
- 379
- References
- 33
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 21 · 2016: 20 · 2015: 21 · 2014: 28 · 2013: 31 · 2012: 28
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- CYP17 inhibitors, steroids, palladium-catalyzed cross-coupling, structure-activity relationship, steroid synthesis, prostate cancer, hormone-dependent prostate cancer, androstenedione, pregnenolone, progesterone
- MeSH terms
- Humans, Male, Magnetic Resonance Spectroscopy, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Steroids, Structure-Activity Relationship, Testis, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.